Company News
BIOOCUS Medical Group's Technology Transfer Enables Pakistan's First Anti-CD19 CAR-T Therapy, Achieving MRD-Negative Remission in Relapsed/Refractory B-ALL
Pakistan has reached a landmark milestone in cellular immunotherapy with the country's first-ever specialized CAR-T cell therapy, made possible through a technology transfer partnership with BIOOCUS Medical Group
BIOOCUS Medical Group’s Dual CD19/BCMA CAR-T Therapy Delivers Promising Results in Refractory Myasthenia Gravis: A Young Patient’s Journey
Academic Breakthrough | Lu Daopei Medical Team Publishes Groundbreaking Clinical Study in the British Journal of Haematology
The Lu Daopei Medical Team, led by Dr. Cao Xingyu and Prof. Lu Peihua, has published an important clinical research paper in the British Journal of Haematology (Impact Factor 5.1). The study investigates the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) after autologous CD7 CAR-T therapy for refractory and relapsed T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (R/R T-ALL/T-LBL).
Multi-Center Study Shows Good Prognosis for Hematologic Malignancy Patients Undergoing MMUD Allogeneic Stem Cell Transplant with ATG
A large multi-center study in China reveals positive outcomes for patients with hematologic malignancies undergoing mismatched unrelated donor (MMUD) stem cell transplants with ATG for GVHD prevention
Patient Story: High-Risk B-ALL, Bone Marrow Transplant at 9 Months, Two Years Later—A Healthy Start for a Young Fighter
A 9-month-old child, diagnosed with high-risk Acute B Lymphoblastic Leukemia (B-ALL), undergoes a successful bone marrow transplant. Two years later, the child is thriving and ready for kindergarten.
Understanding Thalassemia: A Comprehensive Guide to Alpha and Beta Forms
Thalassemia is more than one disease. This guide explores both alpha and beta thalassemia, their causes, symptoms, and the latest treatment options available at BIOOCUS International Medical Center.
Dr. Lu Peihua Presents Breakthrough in CAR-T Therapy at the 29th APBMT Annual Meeting
At the 29th Asia-Pacific Blood and Marrow Transplantation (APBMT) Annual Meeting, Dr. Lu Peihua delivered a keynote address on the success of CAR-T cell therapy in China. Her team’s real-world data from clinical practice received international acclaim, showcasing their contributions to the treatment of blood malignancies.
ASH 2024: Lu Daopei Team Showcases 13 Research Achievements in Hematology
At the upcoming ASH 2024 conference, the Lu Daopei Hospital medical team will present 13 groundbreaking research findings, highlighting advancements in hematology and the potential of CAR-T therapy, reaffirming their commitment to improving patient outcomes.
Overcoming Lymphoma with Dual CAR-T Therapy
After battling lymphoma for three years, a 61-year-old woman achieved complete remission through innovative dual CAR-T therapy at BIOOCUS, showcasing the life-changing potential of advanced cancer treatments.
Bioocus Participates in IGC 2024 to Explore New Partnerships and Business Models in Immuno-Gene and Cell Therapy
Bioocus is excited to join the 8th Immuno-Gene and Cell Therapy Congress (IGC 2024)! We look forward to collaborating with global experts and exploring new business models that match cutting-edge gene and cell therapy technologies. Together, let’s shape the future of immunotherapy.
High Efficacy of CD7 CAR-T Therapy for B-Cell Malignancies: A Breakthrough in Cancer Treatment
The latest research highlights the efficacy and safety of CD7 CAR-T cell therapy in treating relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and T-cell lymphoblastic lymphoma (T-LBL). Conducted by BIOOCUS in collaboration with Lu Daopei Hospital, the study demonstrates promising outcomes for patients, offering a powerful alternative to conventional chemotherapy.
Long-Term Efficacy of CD19 CAR T-Cell Therapy in Treating Relapsed/Refractory Acute Lymphoblastic Leukemia
A groundbreaking study demonstrates the long-term success of CD19 CAR T-cell therapy in treating patients with relapsed/refractory acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation, offering new hope in hematology.